Current Treatment Options in Neurology

, Volume 13, Issue 3, pp 231–241 | Cite as

Tardive Dyskinesia

  • Pratibha G. Aia
  • Gonzalo J. Revuelta
  • Leslie J. Cloud
  • Stewart A. Factor
Movement Disorders

Opinion statement

Tardive dyskinesia (TD) is iatrogenic (drug-induced); hence the best strategy is prevention. Try to limit exposure to any dopamine receptor blocking agents (DRBAs) if possible. These agents may be unavoidable in some psychiatric conditions such as schizophrenia, but alternative therapies can be used in many situations, such as in the treatment of depression, anxiety, gastrointestinal conditions, and other neurologic conditions, including migraines and sleep disorders. When DRBAs are necessary, physicians should prescribe the smallest possible dose and try to taper and stop the drug at the earliest signs of TD. Abrupt cessation should be avoided, as this can worsen symptoms of TD. Always discuss and document the possibility of TD as an adverse effect when starting patients on DRBAs. If TD is mild and tolerable, the withdrawal of the offending agent is possible, and exposure to DRBAs was short, physicians should consider avoiding treatment and waiting for spontaneous recovery. When treatment is necessary, tetrabenazine (TBZ) is considered a potential first-line agent and is known to be one of the most effective drugs in treating TD, but it is expensive and adverse effects such as depression, akathisia and parkinsonism frequently occur. Therefore, second-line agents with better tolerability profiles are often tried first in practice. These include amantadine, benzodiazepines, beta-blockers, and levetiracetam. When using TBZ, adverse effects should be aggressively monitored. (Depression often can be managed with antidepressants, for instance). In patients with psychosis, withdrawal of the antipsychotic may not be possible. Switching to clozapine or quetiapine is one option to minimize TD. When these agents are contraindicated and the patient must continue using other atypical antipsychotic drugs, try to add dopamine-depleting agents such as TBZ or reserpine, but watch for the development of parkinsonism. When the symptoms are focal, such as tongue protrusion or blepharospasm, botulinum toxin injections can be very effective if spontaneous recovery does not occur. As a last resort, when disabling, life-threatening symptoms of TD persist despite all of the above-mentioned methods, some advocate resuming treatment with the DRBA to suppress symptoms of TD. This has the potential to worsen TD in the long run.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Kruse W. Persistent muscular restlessness after phenothiazine treatment: report of 3 cases. Am J Psychiatry. 1960;117:152–3.PubMedGoogle Scholar
  2. 2.
    Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21(2):151–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Rapaport A, et al. Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia. Mov Disord. 2000;15(2):352–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed). 1985;291(6500):930–2.CrossRefGoogle Scholar
  5. 5.
    Wiholm BE, et al. Tardive dyskinesia associated with metoclopramide. Br Med J (Clin Res Ed). 1984;288(6416):545–7.CrossRefGoogle Scholar
  6. 6.
    Jeste DV, Wyatt RJ. Therapeutic strategies against tardive dyskinesia. Two decades of experience. Arch Gen Psychiatry. 1982;39(7):803–16.PubMedGoogle Scholar
  7. 7.
    Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol. 1988;8(4 Suppl):52S–6S.PubMedGoogle Scholar
  8. 8.
    Marsden CD, MRHS, Baldessarini RJ. Extrapyramidal movement disorders produced by antipsychotic drugs. In: Hirsch SR, Bradley PB, editors. Pharmacology and Treatment of Schizophrenia. London: Oxford; 1986.Google Scholar
  9. 9.
    Woerner MG, et al. Diabetes and development of tardive dyskinesia. Am J Psychiatry. 1993;150(6):966–8.PubMedGoogle Scholar
  10. 10.
    Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull. 1992;18(4):701–15.PubMedGoogle Scholar
  11. 11.
    FitzGerald PM, Jankovic J. Tardive oculogyric crises. Neurology. 1989;39(11):1434–7.PubMedGoogle Scholar
  12. 12.
    Fahn S, Jankovic J. Principles and practice of movement disorders. Philadelphia: Churchill Livingstone; 2007.Google Scholar
  13. 13.
    Lang AE. Clinical differences between metoclopramide- and antipsychotic-induced tardive dyskinesias. Can J Neurol Sci. 1990;17(2):137–9.PubMedGoogle Scholar
  14. 14.
    Samie MR, Dannenhoffer MA, Rozek S. Life-threatening tardive dyskinesia caused by metoclopramide. Mov Disord. 1987;2(2):125–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Horiguchi J, et al. Antipsychotic-induced life-threatening ‘esophageal dyskinesia’. Int Clin Psychopharmacol. 1999;14(2):123–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Labbate LA, et al. Tardive dyskinesia in older out-patients: a follow-up study. Acta Psychiatr Scand. 1997;96(3):195–8.PubMedCrossRefGoogle Scholar
  17. 17.
    • Fasano A, Bentivoglio AR. Tetrabenazine. Expert Opin Pharmacother. 2009;10(17):2883–96. PubMedCrossRefGoogle Scholar
  18. 18.
    Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66(3):366–72.CrossRefGoogle Scholar
  19. 19.
    Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999;156(8):1279–81.PubMedGoogle Scholar
  20. 20.
    Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22(2):193–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Huang CC, et al. Evaluation of reserpine and alpha-methyldopa in the treatment of tardive dyskinesia. Psychopharmacol Bull. 1980;16(3):41–3.PubMedGoogle Scholar
  22. 22.
    Huang CC, et al. Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia. Psychopharmacol Berl. 1981;73(4):359–62.CrossRefGoogle Scholar
  23. 23.
    Fahn S. A therapeutic approach to tardive dyskinesia. J Clin Psychiatry. 1985;46(4 Pt 2):19–24.PubMedGoogle Scholar
  24. 24.
    Lieberman JA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry. 1991;158:503–10.PubMedCrossRefGoogle Scholar
  25. 25.
    Bacher NA, Lewis HA. Propranolol, anxiety, and tardive dyskinesia. J Clin Psychiatry. 1983;44(5):196.PubMedGoogle Scholar
  26. 26.
    Perenyi A, Farkas A. Propranolol in the treatment of tardive-dyskinesia. Biol Psychiatry. 1983;18(3):391–4.PubMedGoogle Scholar
  27. 27.
    Pitts FN. Treatment of tardive-dyskinesia with propranolol. J Clin Psychiatry. 1982;43(8):304–4.PubMedGoogle Scholar
  28. 28.
    Schrodt GR, et al. Treatment of tardive-dyskinesia with propranolol. J Clin Psychiatry. 1982;43(8):328–31.PubMedGoogle Scholar
  29. 29.
    Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2000;(2):CD000209.Google Scholar
  30. 30.
    Adler LA, et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry. 1993;150(9):1405–7.PubMedGoogle Scholar
  31. 31.
    Adler LA, et al. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry. 1999;56(9):836–41.PubMedCrossRefGoogle Scholar
  32. 32.
    Thaker GK, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147(4):445–51.PubMedGoogle Scholar
  33. 33.
    Bobruff A, et al. Clonazepam and phenobarbital in tardive dyskinesia. Am J Psychiatry. 1981;138(2):189–93.PubMedGoogle Scholar
  34. 34.
    • Pappa S, et al. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33(6):271–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Angus S, et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997;17(2):88–91.PubMedCrossRefGoogle Scholar
  36. 36.
    Woods SW, et al. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69(4):546–54.PubMedCrossRefGoogle Scholar
  37. 37.
    Slotema CW, et al. Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):507–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Esper CD, Freeman A, Factor SA. Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy. Parkinsonism Relat Disord. 2010;16(7):438–41.PubMedCrossRefGoogle Scholar
  39. 39.
    Hennings JM, Bötzel KE, Wetter TC. Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1167–71.PubMedCrossRefGoogle Scholar
  40. 40.
    Welter ML, Grabli D, Vidailhet M. Deep brain stimulation for hyperkinetics disorders: dystonia, tardive dyskinesia, and tics. Curr Opin Neurol. 2010;23(4):420–5.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Pratibha G. Aia
    • 1
  • Gonzalo J. Revuelta
    • 2
  • Leslie J. Cloud
    • 1
  • Stewart A. Factor
    • 1
  1. 1.Department of NeurologyEmory University School of MedicineAtlantaUSA
  2. 2.Department of NeurologyMedical University of South CarolinaCharlestonUSA

Personalised recommendations